Home › Hidradenitis Suppurativa › Pennsylvania › Philadelphia
Hidradenitis Suppurativa clinical trials in Philadelphia, PA
4 studies for Hidradenitis Suppurativa are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
RecruitingPhase 1
- Clinical Site 8, Philadelphia
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RecruitingPhase 1
- Paddington Testing Co Inc, Philadelphia
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
RecruitingPhase 3
- Investigative Site US074, Philadelphia
- Investigative Site US069, Plymouth Meeting · 12 mi away
Radiotherapy for Refractory Hidradenitis Suppurativa
Recruiting
- Thomas Jefferson University, Philadelphia
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.
More about Hidradenitis Suppurativa on MedlinePlus
Hidradenitis Suppurativa trials in other cities
- Boston, MA9 studies
- Tampa, FL7 studies
- Miami, FL6 studies
- New York City, NY5 studies
- Birmingham, AL5 studies
- Dallas, TX5 studies
- Phoenix, AZ5 studies
- New Orleans, LA4 studies
- Santa Clarita, CA4 studies
- Scottsdale, AZ4 studies
- Durham, NC4 studies
- Minneapolis, MN4 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.